Fluorescent Mouse Embryo Assay for IVF Toxicity Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quality control in in vitro fertilization (IVF) laboratories, such as the mouse embryo assay (MEA), are limited in detecting suboptimal conditions and growth-promoting or inhibiting factors, particularly at early stages of embryo development, and cannot differentiate between morphologically normal but compromised blastocysts and those that are not.
Innovation Solution
A molecular-based mouse embryo assay (mMEA) using transgenic embryos with fluorescent protein markers linked to embryonic pluripotency regulators like Oct-4, Sox2, and Nanog, which assess embryonic development from the one-cell to blastocyst stage, providing qualitative and quantitative analysis to evaluate the impact of culture media and conditions on embryo viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional mouse embryo assay (MEA) with morphological assessment is used, then the method is simple and easy to perform, but it cannot detect suboptimal conditions and compromised blastocysts that appear morphologically normal
Solution Approach 1:
The patent employs fluorescent protein markers (color/optical changes) linked to embryonic pluripotency regulators to detect embryo viability and developmental status. This allows differentiation between morphologically normal but compromised blastocysts and healthy ones through fluorescence signal intensity and pattern analysis, directly resolving the limitation of traditional morphological assessment.
Solution Approach 2:
The patent replaces traditional mechanical/morphological assessment methods with molecular-based fluorescent detection. By using transgenic embryos expressing fluorescent markers under the control of pluripotency gene promoters, the assay transitions from subjective morphological evaluation to objective molecular signal detection, enhancing sensitivity while maintaining operational feasibility.
2Reliability
If molecular-based mouse embryo assay (mMEA) with fluorescent markers is used, then detection sensitivity and ability to detect embryo toxicity are enhanced, but the device complexity and cost increase
Solution Approach 1:
The patent utilizes the embryo's own endogenous pluripotency gene expression patterns to indicate viability and developmental status. The transgenic embryos self-report their physiological state through fluorescent marker expression levels, eliminating the need for external intervention or complex additional reagents, thereby enhancing reliability without proportionally increasing system complexity.
Solution Approach 2:
The fluorescent marker system serves multiple functions simultaneously: it indicates embryo viability, developmental stage, and response to culture conditions. This multi-functionality allows a single assay system to provide comprehensive quality control data, improving reliability while minimizing the need for multiple separate tests.
3Measurement precision
If traditional morphological assessment is used, then the assessment process is quick and simple, but it cannot differentiate between morphologically normal blastocysts and compromised ones
Solution Approach 1:
The patent performs preliminary molecular characterization by establishing fluorescent marker expression patterns at earlier developmental stages. This allows the assay to predict later developmental outcomes and detect compromised embryos before they reach the blastocyst stage, enabling early differentiation of quality without extending the overall assessment timeline significantly.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mMEA offers enhanced sensitivity and ability to detect embryo toxicity and suboptimal conditions earlier than traditional methods, allowing for more accurate assessment of IVF reagents and consumables, ensuring optimal embryo development and pregnancy rates.
Implementation Method 1
transgenic embryos with fluorescent protein markers linked to embryonic pluripotency regulators like Oct-4, Sox2, and Nanog
Data Source
AI summary
A method for qualitatively assessing products used in in vitro fertilization is provided. Also disclosed is an improved quality control assay for use in clinical Assisted Reproductive Technologies (ART).